(BRKR) Bruker - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US1167941087
Stock:
Total Rating 35
Risk 92
Buy Signal -0.14
| Risk 5d forecast | |
|---|---|
| Volatility | 53.8% |
| Relative Tail Risk | -5.75% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.26 |
| Alpha | -42.31 |
| Character TTM | |
|---|---|
| Beta | 1.161 |
| Beta Downside | 0.932 |
| Drawdowns 3y | |
|---|---|
| Max DD | 68.72% |
| CAGR/Max DD | -0.23 |
EPS (Earnings per Share)
Revenue
Description: BRKR Bruker
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper platform for bacterial and fungal identification and establish, DNA test strips, and; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was founded in 1960 and is headquartered in Billerica, Massachusetts.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: -8.60m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -1.65 > 1.0 |
| NWC/Revenue: 27.16% < 20% (prev 22.93%; Δ 4.23% < -1%) |
| CFO/TA 0.02 > 3% & CFO 134.1m > Net Income -8.60m |
| Net Debt (1.57b) to EBITDA (316.0m): 4.97 < 3 |
| Current Ratio: 1.73 > 1.5 & < 3 |
| Outstanding Shares: last quarter (152.5m) vs 12m ago 0.33% < -2% |
| Gross Margin: 46.62% > 18% (prev 0.49%; Δ 4613 % > 0.5%) |
| Asset Turnover: 57.05% > 50% (prev 57.97%; Δ -0.93% > 0%) |
| Interest Coverage Ratio: 1.67 > 6 (EBITDA TTM 316.0m / Interest Expense TTM 57.2m) |
Altman Z'' 3.01
| A: 0.15 (Total Current Assets 2.21b - Total Current Liabilities 1.28b) / Total Assets 6.24b |
| B: 0.38 (Retained Earnings 2.35b / Total Assets 6.24b) |
| C: 0.02 (EBIT TTM 95.7m / Avg Total Assets 6.02b) |
| D: 0.66 (Book Value of Equity 2.47b / Total Liabilities 3.73b) |
| Altman-Z'' Score: 3.01 = A |
Beneish M -3.16
| DSRI: 0.76 (Receivables 544.9m/701.2m, Revenue 3.44b/3.37b) |
| GMI: 1.05 (GM 46.62% / 49.00%) |
| AQI: 1.04 (AQ_t 0.53 / AQ_t-1 0.51) |
| SGI: 1.02 (Revenue 3.44b / 3.37b) |
| TATA: -0.02 (NI -8.60m - CFO 134.1m) / TA 6.24b) |
| Beneish M-Score: -3.16 (Cap -4..+1) = AA |
What is the price of BRKR shares?
As of February 26, 2026, the stock is trading at USD 39.89 with a total of 1,483,717 shares traded.
Over the past week, the price has changed by +0.33%, over one month by -17.65%, over three months by -19.05% and over the past year by -21.38%.
Over the past week, the price has changed by +0.33%, over one month by -17.65%, over three months by -19.05% and over the past year by -21.38%.
Is BRKR a buy, sell or hold?
Bruker has received a consensus analysts rating of 3.86.
Therefore, it is recommended to buy BRKR.
- StrongBuy: 5
- Buy: 2
- Hold: 7
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BRKR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 48.4 | 21.4% |
| Analysts Target Price | 48.4 | 21.4% |
BRKR Fundamental Data Overview February 20, 2026
P/E Forward = 13.8313
P/S = 1.7137
P/B = 2.3809
P/EG = 3.64
Revenue TTM = 3.44b USD
EBIT TTM = 95.7m USD
EBITDA TTM = 316.0m USD
Long Term Debt = 1.98b USD (from longTermDebt, two quarters ago)
Short Term Debt = 16.6m USD (from shortTermDebt, last quarter)
Debt = 1.87b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.57b USD (from netDebt column, last quarter)
Enterprise Value = 7.46b USD (5.89b + Debt 1.87b - CCE 298.8m)
Interest Coverage Ratio = 1.67 (Ebit TTM 95.7m / Interest Expense TTM 57.2m)
EV/FCF = 172.3x (Enterprise Value 7.46b / FCF TTM 43.3m)
FCF Yield = 0.58% (FCF TTM 43.3m / Enterprise Value 7.46b)
FCF Margin = 1.26% (FCF TTM 43.3m / Revenue TTM 3.44b)
Net Margin = -0.25% (Net Income TTM -8.60m / Revenue TTM 3.44b)
Gross Margin = 46.62% ((Revenue TTM 3.44b - Cost of Revenue TTM 1.83b) / Revenue TTM)
Gross Margin QoQ = 47.77% (prev 44.88%)
Tobins Q-Ratio = 1.20 (Enterprise Value 7.46b / Total Assets 6.24b)
Interest Expense / Debt = 0.43% (Interest Expense 8.10m / Debt 1.87b)
Taxrate = 21.0% (US default 21%)
NOPAT = 75.6m (EBIT 95.7m * (1 - 21.00%))
Current Ratio = 1.73 (Total Current Assets 2.21b / Total Current Liabilities 1.28b)
Debt / Equity = 0.76 (Debt 1.87b / totalStockholderEquity, last quarter 2.47b)
Debt / EBITDA = 4.97 (Net Debt 1.57b / EBITDA 316.0m)
Debt / FCF = 36.27 (Net Debt 1.57b / FCF TTM 43.3m)
Total Stockholder Equity = 2.13b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.14% (Net Income -8.60m / Total Assets 6.24b)
RoE = -0.40% (Net Income TTM -8.60m / Total Stockholder Equity 2.13b)
RoCE = 2.33% (EBIT 95.7m / Capital Employed (Equity 2.13b + L.T.Debt 1.98b))
RoIC = 1.80% (NOPAT 75.6m / Invested Capital 4.20b)
WACC = 7.82% (E(5.89b)/V(7.76b) * Re(10.19%) + D(1.87b)/V(7.76b) * Rd(0.43%) * (1-Tc(0.21)))
Discount Rate = 10.19% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.20%
[DCF] Terminal Value 76.59% ; FCFF base≈80.4m ; Y1≈69.9m ; Y5≈55.9m
[DCF] Fair Price = N/A (negative equity: EV 1.05b - Net Debt 1.57b = -522.0m; debt exceeds intrinsic value)
EPS Correlation: -31.53 | EPS CAGR: 5.08% | SUE: -1.01 | # QB: 0
Revenue Correlation: 88.18 | Revenue CAGR: 14.15% | SUE: 0.61 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.23 | Chg7d=-0.159 | Chg30d=-0.173 | Revisions Net=-8 | Analysts=12
EPS current Year (2026-12-31): EPS=2.12 | Chg7d=-0.017 | Chg30d=-0.011 | Revisions Net=-2 | Growth EPS=+15.9% | Growth Revenue=+4.2%
EPS next Year (2027-12-31): EPS=2.42 | Chg7d=-0.008 | Chg30d=-0.026 | Revisions Net=-5 | Growth EPS=+14.0% | Growth Revenue=+4.2%
[Analyst] Revisions Ratio: -1.00 (0 Up / 8 Down within 30d for Next Quarter)
P/S = 1.7137
P/B = 2.3809
P/EG = 3.64
Revenue TTM = 3.44b USD
EBIT TTM = 95.7m USD
EBITDA TTM = 316.0m USD
Long Term Debt = 1.98b USD (from longTermDebt, two quarters ago)
Short Term Debt = 16.6m USD (from shortTermDebt, last quarter)
Debt = 1.87b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.57b USD (from netDebt column, last quarter)
Enterprise Value = 7.46b USD (5.89b + Debt 1.87b - CCE 298.8m)
Interest Coverage Ratio = 1.67 (Ebit TTM 95.7m / Interest Expense TTM 57.2m)
EV/FCF = 172.3x (Enterprise Value 7.46b / FCF TTM 43.3m)
FCF Yield = 0.58% (FCF TTM 43.3m / Enterprise Value 7.46b)
FCF Margin = 1.26% (FCF TTM 43.3m / Revenue TTM 3.44b)
Net Margin = -0.25% (Net Income TTM -8.60m / Revenue TTM 3.44b)
Gross Margin = 46.62% ((Revenue TTM 3.44b - Cost of Revenue TTM 1.83b) / Revenue TTM)
Gross Margin QoQ = 47.77% (prev 44.88%)
Tobins Q-Ratio = 1.20 (Enterprise Value 7.46b / Total Assets 6.24b)
Interest Expense / Debt = 0.43% (Interest Expense 8.10m / Debt 1.87b)
Taxrate = 21.0% (US default 21%)
NOPAT = 75.6m (EBIT 95.7m * (1 - 21.00%))
Current Ratio = 1.73 (Total Current Assets 2.21b / Total Current Liabilities 1.28b)
Debt / Equity = 0.76 (Debt 1.87b / totalStockholderEquity, last quarter 2.47b)
Debt / EBITDA = 4.97 (Net Debt 1.57b / EBITDA 316.0m)
Debt / FCF = 36.27 (Net Debt 1.57b / FCF TTM 43.3m)
Total Stockholder Equity = 2.13b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.14% (Net Income -8.60m / Total Assets 6.24b)
RoE = -0.40% (Net Income TTM -8.60m / Total Stockholder Equity 2.13b)
RoCE = 2.33% (EBIT 95.7m / Capital Employed (Equity 2.13b + L.T.Debt 1.98b))
RoIC = 1.80% (NOPAT 75.6m / Invested Capital 4.20b)
WACC = 7.82% (E(5.89b)/V(7.76b) * Re(10.19%) + D(1.87b)/V(7.76b) * Rd(0.43%) * (1-Tc(0.21)))
Discount Rate = 10.19% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.20%
[DCF] Terminal Value 76.59% ; FCFF base≈80.4m ; Y1≈69.9m ; Y5≈55.9m
[DCF] Fair Price = N/A (negative equity: EV 1.05b - Net Debt 1.57b = -522.0m; debt exceeds intrinsic value)
EPS Correlation: -31.53 | EPS CAGR: 5.08% | SUE: -1.01 | # QB: 0
Revenue Correlation: 88.18 | Revenue CAGR: 14.15% | SUE: 0.61 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.23 | Chg7d=-0.159 | Chg30d=-0.173 | Revisions Net=-8 | Analysts=12
EPS current Year (2026-12-31): EPS=2.12 | Chg7d=-0.017 | Chg30d=-0.011 | Revisions Net=-2 | Growth EPS=+15.9% | Growth Revenue=+4.2%
EPS next Year (2027-12-31): EPS=2.42 | Chg7d=-0.008 | Chg30d=-0.026 | Revisions Net=-5 | Growth EPS=+14.0% | Growth Revenue=+4.2%
[Analyst] Revisions Ratio: -1.00 (0 Up / 8 Down within 30d for Next Quarter)